Hansa Biopharma appoints Achim Kaufhold as CMO to support the expansion outside transplantation

Hansa Biopharma appoints Professor Achim Kaufhold, M.D., a highly experienced senior leader in immunology, infectious diseases and oncology, as Chief Medical Officer. Achim Kaufhold joins the company on June 1st and will be a Member of the Executive Committee. He will support the Company´s expansion outside transplantation and report to Søren Tulstrup, President and CEO.

Lund May 29, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company has appointed  Professor Achim Kaufhold, a very seasoned senior pharmaceutical executive within immunology, infectious diseases and oncology as Chief Medical Officer. Achim Kaufhold brings considerable experience in taking products from early discovery through development to the market. Most recently, he served as CMO and Member of the Executive Committee at Basilea Pharmaceutica in Switzerland.

“I am very happy that we have managed to attract Achim Kaufhold as CMO”, says Søren Tulstrup, President and CEO, Hansa Biopharma. “2020 promises to be a transformative year for our company with the potential EU regulatory approval of imlifidase in kidney transplantation and top line data from the first phase 2 trial in autoimmune diseases. 

Achim Kaufhold´s extensive international experience within the pharmaceutical industry, as well as his track record from successfully bringing products all the way from the laboratory to the bedside of the patient, will add substantial value to our team”. 

“I am excited to join Hansa Biopharm, and I am really impressed by the science and the potential that the immunomodulatory enzyme technology offers across a broad range of indications”, says Achim Kaufhold

“I look forward to contributing to the further development of a commercial stage company and help leveraging the unique technology platform also beyond kidney transplantation”.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for marketing authorization by EMA. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.
 

Subscribe

Documents & Links